insitro milestone-dependent cash risk

This setup makes insitro partly a biotech services business with biotech cost structure risk. Partnership cash can arrive in bursts when a target is picked or a milestone is hit, but the lab payroll, equipment, and wet lab workflows needed to generate new targets keep running every month. That mismatch matters because insitro is not just training models on a laptop, it is paying to run real experiments that partners can pause faster than insitro can shrink its scientific base.1 2 3 4 5

• The partner concentration is concrete. Gilead paid $15M upfront with up to $35M in near term operational payments and milestones on as many as five targets, then all revenue from that collaboration had been fully recognized by January 31, 2022 after Gilead’s option period ended. That is exactly how a collaboration can produce a cash ramp, then go quiet while the platform remains in place.2 3
• Bristol Myers Squibb shows the same milestone logic. The deal started with $50M upfront and up to $20M in near term operational milestones, and insitro later announced $25M tied to discovery progress and selection of a first ALS target. Cash depends on partner decisions to keep advancing targets, not just on insitro continuing the underlying science work.4 5
• The Lilly structure shifts economics again. insitro said the 2024 metabolic disease agreements let it keep global rights to the resulting programs while using Lilly technology. That can create more long term upside, but it also means partnership cash is less like recurring software revenue and more like deal based financing for an expensive drug R&D engine. insitro has raised about $629M in total funding, which helps buffer that volatility but does not remove it.1 6 7

Going forward, the key transition is from selling access to discovery output toward carrying more programs into the clinic. If insitro keeps more rights while partners become more selective on new targets, the company starts to look less like a pure collaboration platform and more like a capital intensive biotech with a powerful sourcing engine and a larger need for follow on financing.1 6 7